MNKD
Trend continuation, possible bullish outlook as long as price can stay above channel.
MNKD (with partner Sanofi) is about to market and distribute FDA approved Afrezza, a inhaled insulin that can make insulin syringes a thing of the past. With diabetes a global condition that effects 371 million people worldwide and is expected to affect 552 million by 2030, MNKD is the only FDA approved product of this kind.
MNKD (with partner Sanofi) is about to market and distribute FDA approved Afrezza, a inhaled insulin that can make insulin syringes a thing of the past. With diabetes a global condition that effects 371 million people worldwide and is expected to affect 552 million by 2030, MNKD is the only FDA approved product of this kind.
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。
免责声明
这些信息和出版物并不意味着也不构成TradingView提供或认可的金融、投资、交易或其它类型的建议或背书。请在使用条款阅读更多信息。